Form 4: Repare Therapeutics EVP, CHIEF SCIENTIFIC OFFICER Michael Zinda Sells Shares to Cover Tax Obligations

Michael Zinda, EVP, CHIEF SCIENTIFIC OFFICER of Repare Therapeutics Inc., sold shares to cover tax obligations related to vested restricted stock units.

Summary

• Michael Zinda, the EVP, CHIEF SCIENTIFIC OFFICER of Repare Therapeutics Inc., reported the sale of common shares on March 28, 2024, and April 1, 2024.
• The sales were executed to cover tax withholding obligations related to the vesting of restricted stock units (RSUs).
• A total of 450 shares were sold on March 28, 2024, at a weighted average price of $4.64, and 410 shares were sold on April 1, 2024, at a weighted average price of $4.66.
• These transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2023.
• Following these transactions, Zinda directly owns 71,908 common shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports routine share sales for tax purposes under a pre-existing trading plan. There is no indication of positive or negative implications for the company's performance.

Industry Context

Sales of shares by company executives are common and often related to compensation and tax obligations. The use of a 10b5-1 trading plan suggests the sales were pre-planned and not based on insider information.

Comparison to Industry Standards

• Executive share sales to cover tax obligations are a standard practice across the industry.
• Companies like Amgen, Gilead, and Regeneron often see similar filings from their executives.
• The use of 10b5-1 plans is also a common practice to avoid accusations of insider trading.

Stakeholder Impact

• The share sales are unlikely to have a significant impact on shareholders as they are related to tax obligations and executed under a pre-arranged trading plan.

Key Dates